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Abstract
Background: In an effort to promote healthy ageing and preserve health and function, the government of Chile
has formulated a package of actions into the Programme for Complementary Food in Older People (Programa
de Alimentación Complementaria para el Adulto Mayor - PACAM). The CENEX study was designed to evaluate
the impact, cost and cost-effectiveness of the PACAM and a specially designed exercise programme on pneumonia
incidence, walking capacity and body mass index in healthy older people living in low- to medium-socio-economic
status areas of Santiago. The purpose of this paper is to describe in detail the methods that will be used to
estimate the incremental costs and cost-effectiveness of the interventions.
Methods and design: The base-case analysis will adopt a societal perspective, including the direct medical and
non-medical costs borne by the government and patients. The cost of the interventions will be calculated by the
ingredients approach, in which the total quantities of goods and services actually employed in applying the
interventions will be estimated, and multiplied by their respective unit prices. Relevant information on costs of
interventions will be obtained mainly from administrative records. The costs borne by patients will be collected
via exit and telephone interviews. An annual discount rate of 8% will be used, consistent with the rate
recommended by the Government of Chile. All costs will be converted from Chilean Peso to US dollars with the
2007 average period exchange rate of US$1 = 522.37 Chilean Peso. To test the robustness of model results, we
will vary the assumptions over a plausible range in sensitivity analyses.
Discussion: The protocol described here indicates our intent to conduct an economic evaluation alongside the
CENEX study. It provides a detailed and transparent statement of planned data collection methods and analyses.
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Background
The United Nations Population Division has estimated
great increases in both the proportion and absolute size of
the older person population over the next fifty years [1].
At the 2nd World Assembly on Ageing, policy initiatives
were proposed to promote active and healthy lifestyles in
later life [2]. Emphasis was placed, among other things,
on adequate nutrition throughout the life course and
national food policies designed to recognise older people
as potentially vulnerable. The aim was to increase healthy
life-years in older people, and thereby decrease the
number of years, and the proportion of time, spent in
poor health. Some governments have responded to these
increased demands by designing innovative programmes
aimed at tackling the twin problems of food and nutrition
insecurity among older people [3]. For example, food bas-
kets are still popular in some parts of Latin America, and
community kitchens have also been experimented with,
particularly in Argentina. In Mexico City, the local govern-
ment provides a universal pension transferred electroni-
cally to a plastic debit card which can be used in
supermarkets.
Chile is currently undergoing a period of rapid demo-
graphic transition which has led to an increase in the pro-
portion of older people in the population. Many older
people in Chile are socially and nutritionally vulnerable,
and this has placed great demands on the national health
care system which has limited human resources and
budget. To promote healthy ageing, the Government of
Chile has initiated a programme of nutritional supple-
mentation which may have considerable positive benefits
for the health and function of older people.
The overall aim of the Programme for Complementary
Food in Older People (Programa de Alimentación Comple-
mentaria para el Adulto Mayor – PACAM) is to contribute to
improvements in health and quality of life among older
people in Chile. In order to be eligible for the programme,
individuals must be registered at their local health centre
and be 70+ years of age.
Chile's approach to nutrition and health care has been
criticised as being too expensive for most low- and mid-
dle-income countries [3], and no information is currently
available on the cost-effectiveness of the supplementation
programme. Therefore there is interest in evaluating the
cost-effectiveness of PACAM. At the same time, there have
also been calls in Chile to enhance the performance of
PACAM by including a physical activity component  [4].
Here we present a summary of economic evaluation
methods being applied in the CENEX study
[ISRCTN48153354]. The design of the main study is
described in detail elsewhere [4]. Briefly, as the nutritional
supplements are distributed to older people at health cen-
tres, and the exercise programme is also offered to groups,
the study was designed as a 2 × 2 factorial cluster-ran-
domised controlled trial of the effect of a two year inter-
vention. The interventions consisted of either a
nutritional supplement, or an exercise programme, or
both, or neither. The primary outcomes are the incidence
of pneumonia and walking capacity among adults aged
65.0–67.9 years at baseline living in low- to medium-
socio-economic status areas of Santiago, Chile.
Methods and design
Economics is gaining increasing importance in health care
practice and research. Economic evaluation methods pro-
vide a framework to inform programme planners about
the viable options for intervention, and the levels at which
they would best be implemented, taking into account the
objectives of the intervention. This study has been
designed to include an economic evaluation alongside a
cluster-randomised controlled trial.
Economic evaluation requires specification of
• the frames of the study;
• the interventions;
• the health outcomes;
• the 'economic' outcomes;
• data presentation and analysis; and
• sensitivity analysis.
Framing the economic evaluation
The first step to conducting an economic evaluation is to
frame the study. Decisions made at this stage directly
determine which costs and outcomes are considered rele-
vant and should therefore be included in the analysis. This
means that choices made in the framing of the evaluation
will have an impact on the final results of an analysis.
The target audience includes all persons or institutions
that will use the results of the study to make decisions. For
this study the primary target audience is the Chilean Min-
istry of Health. Secondary audiences include older Chil-
ean adults themselves, as well as policy-makers and older
adults in other relevant settings.
The study question of an economic evaluation should be
well-defined, stated in an answerable form and relevant to
the decision facing the target audience. For this study the
study question is two-fold: (i) can nutritional supplemen-
tation and physical exercise prevent disease and func-
tional disability in later life, i.e. do they work?, and (ii) if
so, are they worth it?, i.e. do they represent an efficient use
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of resources? The focus of this paper is on the methods to
assess the efficiency, rather than the effectiveness, of the
interventions.
The choice of perspective, or viewpoint, determines the
scope of the costs and benefits. For this study we will
adopt a health system and societal perspective. The target
population of this study is participants aged 65.0–67.9
years at baseline who lived within the defined catchment
area of the selected health centres. The time frame for the
CENEX trial is two years. This does not allow the full long-
term cost and benefits to be measured. Therefore, some
modelling is planned and is described in more detail
below with respect to the calculation of health outcomes.
What are the interventions?
There are two components of the nutrition intervention
within PACAM: one is a powdered food called Golden
Years (Años Dorados), which is composed of a cereal and
legume mix fortified with vitamins and minerals; the
other called Bebida Láctea is a similarly fortified low-lac-
tose powdered milk. Every beneficiary is entitled to collect
a one-kilo sachets of each product from their local health
post, health centre or hospital each month.
For the exercise intervention, participants are individually
invited to attend two physical activity training sessions per
week of one hour each. Training consists of a period of
warming up and three levels of chair stands, three levels of
modified squats, three levels of step-ups onto a stair, and
six sets of 15 repetitions of arm pull-ups using rubber
bands of variable resistance. Special exercises are delivered
to participants with specific physical limitations. Partici-
pants are encouraged to walk to the exercise classes (up to
20 minutes from home) as part of the exercise protocol.
Participants unable to attend classes are advised about
exercises that could be conducted in their homes.
What are the health outcomes?
The primary outcome for the nutrition intervention
(PACAM) will be the incidence of pneumonia over a two-
year period after the initiation of the intervention. The
study is using the following operational definitions of
pneumonia:
1. Hospitalised cases of pneumonia – J10-J12 (viral) and
J13-J18 (bacterial);
2. Health centre diagnosed and treated pneumonia.
The primary outcome for the exercise intervention will be
walking capacity (distance walked in six minutes)
assessed two years after initiation of the intervention.
The following secondary outcomes will be considered:
- Body mass index [BMI weight (kg)/height (m)2] as a
measure of potential interaction between the two
interventions;
- Measure of self-reported health status (Short-Form
36);
- Measure of depression (GDS-15);
- Self-reported incidence of chronic diseases (diabetes,
hypertension, coronary heart disease, stroke, heart
failure) from baseline to 24 months after the initiation
of the intervention;
- Self reported productive activity in the household
and community;
- Self-reported incidence of falls from baseline to 24
months after the initiation of the intervention;
- Self-reported incidence of fracture from baseline to
24 months after the initiation of the intervention;
- Blood pressure;
- Anthropometry (waist circumference, triceps skin-
fold thickness, mid-arm circumference, calf circumfer-
ence, hand-grip strength;
- Timed up-and-go assessment;
- Blood indicators of cardiovascular disease risk and
insulin resistance (in a sub-sample).
In addition to these measures of self-reported health sta-
tus, morbidity and function, we will also consider the
impact of the interventions on reducing mortality. We will
use evidence on the association between walking capacity
(distance and speed) and mortality risk to extrapolate our
intermediate endpoints (distance walked in 6 minutes
and timed up-and-go assessment) to final outcomes.
Walking speed represents a powerful predictor of health-
related events in older persons [5]. Ostir et al. [6] illus-
trated that walking speed alone can provide similar infor-
mation on mortality risk to a more comprehensive
summary measure of physical performance. Finally, we
plan to calculate quality-adjusted life-years (QALYs) using
self-reported health-related quality of life data collected
with the SF-36 instrument. Estimates of lifetime QALYs
will be based on predicted life expectancy using age- and
gender-specific period mortality rates for the population
of Santiago, Chile.
What are the 'economic' outcomes
The following section provides a description of the meth-
ods for estimating the costs of providing and accessing the
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interventions. These costs will also be supplemented by
the costs of treating the disease(s) the intervention(s)
aims to avoid and the additional health care the interven-
tion(s) might trigger. These data will be collected over the
intervention period using a range of methods.
Patient costs will be assessed via:
- exit interviews of study participants to ascertain the
costs of accessing the interventions (PACAM and exer-
cise classes). A questionnaire will be administered by
local interviewers, and includes closed questions (with
options for 'no response' and 'don't know') asking
how the participants travelled to the health facility (to
collect the supplement or to receive care) or the exer-
cise classes, the cost of their travel, how much time
they spent both travelling and at the facility/class. To
estimate opportunity costs, we will also ask about
what they would have been doing otherwise, includ-
ing lost earnings (if employed);
- case-based sampling in which individuals who have
experienced episodes of pneumonia and acute respira-
tory infections will be identified, contacted and inter-
viewed by telephone, in order to estimate the costs
borne by them, and any caregivers. In the interviews,
information will be collected on both hospitalised
and non-hospitalised patients, including: transporta-
tion costs borne by the patient and carer(s); costs of
care, number of days out of work (or other productive
unpaid activities), income lost by patient and carer(s)
(if employed).
The opportunity cost of the participants' or patients' time
will be valued in monetary units, using a range of different
approaches. These data will not be combined with out-of-
pocket expenses. There is not a consensus among econo-
mists on a single appropriate valuation method. For
example, we will use an estimate based on stated losses of
each group, valued at average wage rates for people aged
65–67 years of age. We will use our data on activities that
would have been carried out if they were not at the health
centre or exercise class, and try to obtain appropriate
shadow wage rates where these activities are non-remu-
nerated.
Provider costs will be assessed via:
- defining the types, quantities and prices of the differ-
ent components required to deliver the interventions
(PACAM and exercise classes) at the health centres
and/or community centres by reviewing expenditure
and budget records. Given that the major set-up costs
of the national primary health infrastructure, through
which PACAM is delivered, are already covered, the
additional cost of implementing PACAM corresponds
to the incremental cost associated with the distribu-
tion of the two nutritional supplements and the asso-
ciated staff time. Indeed, sufficient staff time may
already exist. The annual equivalents of all capital
costs will be calculated on the basis of lifetimes appro-
priate to each item. An annual discount rate of 8% will
be used, consistent with the rate recommended by the
Government of Chile.
- case-based sampling, in which the medical records of
individuals who have experienced episodes of pneu-
monia and acute lower respiratory infections will be
identified, information will be collected on both hos-
pitalised and non-hospitalised patients, including:
length of stay; number of emergency room visits;
drugs consumed and tests performed.
- analysis of existing data on health centre utilisation
rates will be used to measure differences in utilisation
between the trial arms, and we will identify unit costs
associated with the different services provided or
averted. The costs of providing these services, e.g. diag-
noses and treatment of the secondary outcome varia-
bles such as diabetes, hypertension, coronary heart
disease, stroke, heart failure and fractures, will be esti-
mated based on the Ministry of Health reference costs
(available on the website of AUGE – Acceso Universal
para prestaciones integrales y Garantías Explícitas asocia-
das a la atención de prioridades). Because full analysis of
the costs of these secondary outcome variables is
beyond the scope of the current study, the user costs
for these services will be modelled from data collected
on pneumonia and acute lower respiratory infection
cases.
All costs will be converted from Chilean Peso to US dol-
lars with the 2007 average period exchange rate of US$1 =
522.37 Chilean Peso. All setup costs and other costs
related to the CENEX study will be excluded; these include
costs associated with trial administration, data collection,
and actual measurement of clinical outcomes as per the
trial protocol. Because no previous costing studies could
be called upon to give a sense of the expected variation, we
did not conduct a formal power calculation to determine
the sample size for the data collection activities. Instead,
the size of samples required for the collection of these
data will be calculated once the overall variability of the
key measures is determined – to this end, we plan to begin
with the preliminary samples sizes indicated in Table 1.
Data presentation and analysis
Costs falling upon the health sector, patients or their fam-
ilies will be presented in total and disaggregated form.
Resource use and unit costs will be used to estimate mean,
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medians, standard deviations and ranges of costs for the
samples of participants in the CENEX study.
We will consider two types of economic evaluation. If
there is some evidence of clinical differences between
interventions, the incremental costs and effects between
the interventions will be combined to estimate the incre-
mental cost-effectiveness of one intervention over
another, i.e. a cost-effectiveness analysis (CEA). This will
identify the cost associated with a given change in health
effect represented in terms of an incremental cost-effec-
tiveness ratio (ICER). If one intervention is both more
effective and less costly than the other, and if there are no
other unmeasured factors which would alter choices, then
it is dominant and should be adopted widely. If one inter-
vention is more effective and more costly than the other,
then the results will inform the extra cost to society of an
increase in a specified health gain.
Additionally, we will consider cost-utility analysis (CUA)
where consequences are measured in term of utility
(QALYs). This form of evaluation reflects quantity and
quality of life changes as a result of the interventions in a
single composite measure. We will reflect on the potential
bias of using utility measures such as the QALY since we
require reliable and valid measures for application to
older population groups that can also be used within the
context and for the purpose of economic evaluation. For
example, what is the impact of age on assessments of
patient-focused health status (including patient-reported
outcomes) and health-related quality of life (HRQOL)?
Do existing measures inherently bias cost-effectiveness
results against the particular group of older people (due to
older patients being less likely to benefit for long periods
of time from an intervention compared to younger age
groups)? Does the QALY adequately represent the health
gains experienced by older people? For example, Donald-
son et al. [7] described QALYs as being inappropriate for
evaluating long-term care for older people due to its
insensitivity to changes in health status within this con-
text.
In economic evaluations of health care interventions to
date, many analysts have simply presented results without
interpretation or recommendation; furthermore, defini-
tions of the threshold, or ceiling ratio, have been left
largely to the discretion of the analyst. The ceiling ratio
represents a decision maker's valuation of a unit of health
gain and is a particularly crucial and politically sensitive
element of economic evaluation as it is the relative value
against which the acceptability of ICERs are judged. If the
value of an ICER is below the ceiling ratio, an intervention
is deemed acceptable on grounds of cost-effectiveness.
Based on the recommendation of the Commission on
Macroeconomics and Health (CMH) [8], WHO classifies
interventions as 'highly cost-effective' for a given country
if results show that they gain a QALY for less than the per
capita national GNI or GDP. In 2007, GNI per capita in
Chile was estimated to be $8,350. We will also place the
findings in broader context by comparing them to other
economic evaluations that have been undertaken in Chile
or neighbouring countries after adjustments have been
made for inflation.
Before any conclusions are made, any assumptions and
uncertainties will be tested using sensitivity analysis. Sen-
sitivity analysis will help in the evaluation of the reliabil-
ity of the conclusions for the particular context of the trial
and will also facilitate consideration of the generalisabil-
ity of results within and beyond Chile.
It would be beneficial to health care decision makers if
economic study results could be generalised from one set-
ting to another as this would avoid having to repeat every
study in every setting. Factors which may vary in different
settings are: access to care, unit costs of resources, geo-
graphical variations in demography or epidemiology of
disease, clinical practice patterns and quality of care, and
availability of resources. To facilitate estimation of the
transferability of economic data from the CENEX study to
other health care settings both within and beyond Chile,
such factors in the study population will be described, and
resource use and prices reported separately.
Ethical approval
The protocol for this study has been approved by the Insti-
tutional Review Board at Instituto de Nutrición y Tec-
nología de los Alimentos, University of Chile, and by the
London School of Hygiene and Tropical Medicine ethics
committee.
Discussion
The CENEX study and associated economic evaluation
provide a unique opportunity to measure the costs and
cost-effectiveness of a nutrition supplement and an exer-
cise programme prospectively, alongside the actual health
care processes for which effectiveness is being measured.
Table 1: Summary of the preliminary sample sizes
Patient costs
Cost of accessing PACAM 100 exit interviews
Cost of accessing the exercise programme 100 exit interviews
Cost of hospitalised pneumonia 10 telephone interviews
Cost of ambulatory pneumonia 25 telephone interviews
Cost of ambulatory pneumonia 25 telephone interviews
Provider costs
Cost of hospitalised pneumonia 10 medical records
Cost of ambulatory pneumonia 25 medical records
Cost of ambulatory ARI 25 medical records
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In this paper, the methods have been described for evalu-
ating whether these interventions will be cost-effective.
Presenting this methodology paper before the end of the
trial makes transparent the methods used for the evalua-
tion. In our view it is important to record our methods in
detail before publication of the results of the trial so that
a record of detail not normally found in the final trial
reports can be made available in the public domain.
There may be broader, long-term economic effects on the
population or health service that, because of the scope of
the CENEX study, have not been accounted for in the
instruments used to assess the clinical and economic com-
ponents. For example, wider benefits may include the
value attached by the participants to the process of receiv-
ing such services. Indeed a number of studies have shown
that in low- and middle-income countries, older people
are less respected and less valued than their healthier
counterparts [9,10]. Benefits may also derive from institu-
tional change. Institutions, in this sense, are defined as the
patterns of behaviour that determine how individuals,
groups and organisations interact with one another [11]
and may be either informal (e.g. various norms of behav-
ior) or formal (legislation, government policy, regula-
tions). Institutions are relevant to programmes for older
people since they are defined by specific relationships – in
particular those they establish between providers and cli-
ents (and the wider community). The development of
such relationships, to some extent, alters the nature of the
community itself e.g. they may increase the level of trust
in health services and individuals' willingness to use such
services which, in turn, may influence the effectiveness of
future programmes. Holistic approaches to carrying out
economic evaluation using institutionalist methods to
account for some of these broader issues have recently
been examined [12], although these themes have gener-
ally not been well recognised in economic evaluation.
Incorporation of economic evaluations within (cluster)
randomised controlled trials of public health interven-
tions has been a growing trend in the past decade [13,14].
Many health care systems now use economic evaluations
as a formal input to decisions about whether to fund pro-
grammes. Although there is an expressed need for eco-
nomic evaluation in Latin America, very few examples of
the use of such studies exist. A survey conducted by Igle-
sias et al. [15] showed that decisions regarding the alloca-
tion of resources to different areas of health care in Latin
America are mainly driven by governmental policies. Fur-
thermore, the lack of a clearly defined set of criteria to
facilitate or guide the decision-making processes within
the Latin American health-care systems was identified as
one of the main obstacles preventing the use of economic
evaluation studies. Given that this study is supported by
the Ministry of Health in Chile, we are confident that it
will have an influence on policy and practice.
Conclusion
Unprecedented changes in the demographic characteris-
tics of countries worldwide mean that we are all con-
fronted by the challenge of preparing to meet the
demands of an ageing society. In the face of current demo-
graphic trends, increasing health care costs, and concerns
about the quality of health care, the financing and deliv-
ery of care for older people is a critical health care policy
challenge. A focused research effort to determine how
health care systems can most cost-effectively prevent disa-
bility, reduce functional decline, and extend active life
expectancy in older people such as that described here for
the CENEX study will provide decision-makers with the
information needed to tackle age-specific disability rates
and to allocate limited resources efficiently. These meth-
ods should also be of use for the economic evaluation of
similar nutrition and exercise programmes.
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